RecruitingNCT07224789
Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA
Sponsor
City of Hope Medical Center
Enrollment
600 participants
Start Date
Jan 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. This study aims to develop a non-invasive liquid biopsy assay using plasma-derived cell-free circular RNAs (cf-circRNAs) for early and accurate detection of colorectal cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Adults (≥18 years old)
- Histologically confirmed colorectal cancer (Stage I-III)
- Availability of pre-treatment plasma samples
- Written informed consent provided
Exclusion Criteria3
- History of other active malignancies within the past 5 years
- Poor sample quality or hemolysis
- Inability to provide informed consent
Interventions
DIAGNOSTIC_TESTcf-circRNA assay
Circular RNA detection in plasma or serum by RT-qPCR
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07224789
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations